





- (51) **International Patent Classification:**
A61K 31/55 (2006.01) *A61K 31/5377* (2006.01)
- (21) **International Application Number:**
PCT/US2011/056135
- (22) **International Filing Date:**
13 October 2011 (13.10.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/392,515 13 October 2010 (13.10.2010) US
- (71) **Applicant (for all designated States except US):** **MILLENNIUM PHARMACEUTICALS, INC.** [US/US]; 40 Landsdowne Street, Cambridge, MA 02139 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **FREEZE, Brian, S.** [US/US]; 67 Gates Street, Unit 1, Boston, MA 02127 (US). **HIROSE, Masaaki** [JP/JP]; c/o Takeda Pharmaceutical Company Limited, Oncology DDU,C-1 2F 1110, 26-1 Muraokahigashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **HONG MYUNG, Lee** [US/KR]; 118 Amory Street, Cambridge, MA 02139 (US). **SELLS, Todd, B.** [US/US]; 32 Ray Avenue, Bellingham, MA 02019 (US). **SHI, Zhan** [US/US]; 18 Shagbark Road, Concord, MA 01742 (US). **TAKAOKA, Leo, R.** [US/US]; 2366 Commonwealth Avenue #2-2, Newton, MA 02466 (US). **VYSKOCIL, Stepan** [CZ/US]; 34 Eustis Street, Arlington, MA 02476 (US). **XU, Tianlin** [US/US]; 2 Arrowhead Drive, Shrewsbury, MA 01545 (US).
- (74) **Agents:** **SHAIR, Karoline, K.M.** et al.; Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, MA 02139 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) **Title:** HETEROARYLS AND USES THEREOF

(57) **Abstract:** This invention provides compounds of formula I-A or I-B: wherein HY, G₁, G₂, R², R¹², W₁, W₂, n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.